Human
Growth Hormone/Steroids Statutory Overview
|
A. Historical overview
1. Prosecuting under the
FDCA
The distribution of anabolic steroids and/or human growth
hormone for muscle enhancement purposes may involve conduct designed both to
defraud the United States and to violate federal law. Since 1938, federal law
has prohibited the distribution of anabolic steroids and/or human growth
hormone outside a legitimate doctor-patient relationship. Originally, the
government's principal legal claim was made under the Federal Food, Drug, and
Cosmetic Act and involved allegations that individuals were distributing
anabolic steroids and/or human growth hormone, both of which are prescription
drugs, without a prescription. See 21 U.S.C. § 353(b)(1)(B).
Pursuant to this statute, prescription drugs such as anabolic steroids and/or
human growth hormone could be legally distributedonly in those
instances in which a physician, based upon an individualized determination of
a proper course of treatment, authorizes the drug's distribution to a patient
under his supervision. See Brown v. United States,
250 F.2d 745, 746-47 (5th Cir.), cert. denied, 356
U.S. 938 (1958); DeFreese v. United States, 270 F.2d 730, 733
& n.5 (5th Cir. 1959), cert. denied, 362 U.S. 944
(1960); see also United States v. Zwick,
413 F. Supp. 113, 115 (N.D. Ohio 1976). If prescription drugs are distributed
outside of this relationship, then the drugs are deemed misbranded. See 21
U.S.C. § 353(b). Distribution of prescription drugs outside these
restrictions has resulted in the prosecution and conviction of
laypersons,[FN1] pharmacists,[FN2] and physicians.[FN3]
FN1. E.g., United
States v. Shields, 939 F.2d 780 (9th Cir. 1991), superseded after remand by,United
States v. Von Mitchell, 984 F.2d 338 (9th Cir. 1993).
FN2. E.g., United
States v. Siler Drug Store, 376 F.2d 89 (6th Cir. 1967).
FN3. E.g., DeFreese, supra; Brown, supra.
If such illegal distribution of anabolic steroids and/or
human growth hormone was done with the intent to defraud and mislead either
consumers or the state and federal government agencies regulating these
drugs, the conduct was punishable as a three-year felony.[FN4] 21 U.S.C. §
333(a)(2); see United States v. Cambra, 933 F.2d 752,
755 (9th Cir. 1991).
FN4.
Using the Federal Food, Drug, and Cosmetic Act, the government must establish
an interstate nexus. Thus, the government must prove either that any one of
the components of the anabolic steroids and/or human growth hormone travelled
in interstate commerce before the drug was misbranded and held for sale, see 21
U.S.C. § 331(k), or the government must establish that the individual caused
the delivery for introduction into interstate commerce of the misbranded
human growth hormone and/or misbranded anabolic steroids, see 21
U.S.C. § 331(a).
2. The 1988 Amendments
In recognition of the fact that illegal drug trafficking
in anabolic steroids and human growth hormone was becoming larger in scope
and presenting an ever-increasing health risk to young athletes, Congress
addressed the issue with two amendments, first in 1988 and then later in
1990. The purpose of both of these amendments was to criminalize steroid and
human growth hormone trafficking.
The first of these amendments was enacted as part of the
1988 Anti-Drug Abuse Amendments, Pub.L. No. 100-690, §§ 2401, 2403, and took
effect on November 18, 1988. The 1988 Anti-Drug Abuse Amendments had two
important components. The first was the creation of a new statute (codified
at 21 U.S.C. § 333(e)(1)) which made the distribution of anabolic steroids
illegal unless (1) it was done pursuant to the order of a physician, and (2)
it was for the purpose of treating a disease. Pub.L. No. 100-690, § 2403. The
second weapon that Congress added in 1988 to the government's arsenal to halt
illegal trafficking in anabolic steroids and/or human growth hormone was the
enactment of Pub.L. No. 100-690, § 2401. This provision, which was codified
as 21 U.S.C. § 333a, gave the government the authority to seek forfeiture of
property for felony crimes relating to any violations of the
Federal Food, Drug, and Cosmetic Act involving anabolic steroids or human
growth hormone. In pertinent part, 21 U.S.C. § 333a, provided:
Any
conviction for a violation of section 303(e) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. § 333(e)), or any other provision of that Act,
involving an anabolic steroid or a human growth hormone shall be considered,
for purposes of section 413 of the Controlled Substances Act (21 U.S.C. §
853), a conviction for a violation of title II of the Comprehensive Drug Abuse
Prevention and Control Act of 1970, if such violation of the Federal Food,
Drug, and Cosmetic Act is punishable by imprisonment for more than one year.
3. The 1990 Amendments
In 1990, Congress enacted more stringent controls with
higher criminal penalties for offenses involving the illegal distribution of
anabolic steroids and human growth hormone. This new legislation, which was
enacted as part of the Anabolic Steroids Control Act, Pub.L. No. 101-647,
title XIX, §§ 1901-05, resulted in a reconfiguration of the statutory scheme
regulating the distribution of both anabolic steroids and human growth
hormone. The 1990 Act reclassified anabolic steroids as Schedule III
controlled substances, effective February 27, 1991.[FN5] See 21
U.S.C. § 812(c) (1992). The 1990 Act also amended 21 U.S.C. § 333(e)(1) to
explicitly criminalize as a five-year felony the distribution and possession,
with intent to distribute, of human growth hormone "for any use . . .
other than the treatment of a disease or other recognized medical condition,
where such use has been authorized by the Secretary of Human Services . . .
and pursuant to the order of a physician . . . ."[FN6] Pub.L. No.
101-647, title XIX, § 1904 (codified at 21 U.S.C. § 333(e)(1) (1992)). The
1990 Act also provided that criminal forfeiture would be available as an
additional penalty for convictions involving illegal distribution of human
growth hormone under the newly amended 21 U.S.C. § 333(e)(1). See Pub.L.
No. 101-647, title XIX, § 1904 (codified as 21 U.S.C. § 333(e)(3) (1992)).
FN5.
Although U.S.C.A. still lists 21 U.S.C. § 333(e)(1) as prohibiting the
distribution of anabolic steroids, it should be noted this provision has not
been in effect since February 27, 1991.
FN6.
If human growth hormone is distributed to individuals under the age of 18,
the amendments increase the maximum term of imprisonment to 10 years. Pub.L.
No. 101-647, title XIX, § 1904 (codified at 21 U.S.C. § 333(e)(2)).
In 1993, these provisions outlawing the distribution of
human growth hormone for non-medical purposes were recodified at 21 U.S.C. §
333(f) pursuant to Pub.L. No. 103-80, § 3(e), 107 Stat. 775.
B.Practical Considerations
Prosecuting distribution of human growth hormone is
different from virtually any other drug prosecution under the FDCA. Among
other things, proof of interstate distribution of the drug is unnecessary.
Additionally, the mens rearequirement for a felony is
"knowing distribution" or "knowing possession with intent to
distribute," not "intent to defraud or mislead."
Thus, prosecuting non-physicians for distributing human
growth hormone is akin to prosecuting a narcotics case under the Controlled
Substances Act. As a result, establishing liability in such cases is simpler
than for other FDCA offenses. This is particularly true because the only two
authorized manufacturers of human growth hormone (Genentech and Eli Lilly)
have both established stringent restrictions over the distribution of their
products to ensure that only physicians can gain access to the drugs. Under the
current restrictions, only hospital pharmacies can order the drug; local
pharmacies cannot. Thus, most non-physician cases involving the distribution
of human growth hormone will involve one of three scenarios: (1) diverted
human growth hormone, obtained either through theft or via a drug-dealing
physician; (2) smugg |
Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Showing posts with label United States Attorney's Manual Human Growth Hormone/Steriods. Show all posts
Showing posts with label United States Attorney's Manual Human Growth Hormone/Steriods. Show all posts
Monday, July 29, 2013
What the United States Attorney's Manual Says About Human Growth Hormone/Steriods
Subscribe to:
Posts (Atom)